{"transactions":[{"id":932217,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:35:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":262500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":6.41,"underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0000905148-26-000323","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000323/form4.xml","form_type":"4"}},{"id":932216,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"officer":true,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-23T16:35:24.000Z","date":"2026-01-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. (\"BioCryst\"), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an \"In-the-Money Option\") that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."}],"balance_after":0,"derivative":{"exercise_price":3.87,"underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000905148-26-000323","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000090514826000323/form4.xml","form_type":"4"}},{"id":1192175,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-25T16:05:11.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":262500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 21, 2025 and is subject to vesting over a four-year period, with 25% of the 262,500 shares underlying the option upon grant vesting on the first anniversary of February 13, 2025 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":262500,"derivative":{"exercise_price":6.41,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":262500},"source":{"system":"sec-edgar","filing":"0001104659-25-027765","document":"tm2510055-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465925027765/tm2510055-1_4seq1.xml","form_type":"4"}},{"id":1549365,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-03T16:05:13.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":80000,"derivative":{"exercise_price":3.87,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-24-043092","document":"tm2410392-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924043092/tm2410392-1_4seq1.xml","form_type":"4"}},{"id":1549364,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-03T16:05:13.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":13.5939,"value":135939.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.76, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-043092","document":"tm2410392-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924043092/tm2410392-1_4seq1.xml","form_type":"4"}},{"id":1549363,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-03T16:05:13.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":3.87,"value":38700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-24-043092","document":"tm2410392-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924043092/tm2410392-1_4seq1.xml","form_type":"4"}},{"id":1649098,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T16:06:17.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 8, 2024 and is subject to vesting over a four-year period, with 25% of the 175,000 shares underlying the option upon grant vesting on the first anniversary of February 8, 2024 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":175000,"derivative":{"exercise_price":15.26,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001104659-24-014618","document":"tm245876-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924014618/tm245876-6_4seq1.xml","form_type":"4"}},{"id":1666442,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":false,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":90000,"derivative":{"exercise_price":3.87,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1666441,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":false,"shares":800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was granted on August 1, 2022, pursuant to the Issuer's 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vested on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":99200,"derivative":{"exercise_price":3.87,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1666440,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-29","kind":"sale","planned":true,"acquired":false,"shares":9200,"price":11.147,"value":102552.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1666439,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-29","kind":"exercise","planned":true,"acquired":true,"shares":9200,"price":3.87,"value":35604.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."}],"balance_after":9200,"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1666438,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":800,"price":11.015,"value":8812.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.00 to $11.02, inclusive. The reporting person undertakes to provide to Astria Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1666437,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-30T17:03:13.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":true,"shares":800,"price":3.87,"value":3096.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on March 31, 2023."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0001104659-24-008327","document":"tm244587-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465924008327/tm244587-1_4seq1.xml","form_type":"4"}},{"id":1865094,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-06T08:04:20.000Z","date":"2023-06-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the \"Company\") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the \"Stock Plan Amendment Proposal\"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 90,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments."}],"balance_after":90000,"derivative":{"exercise_price":13.36,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001104659-23-068337","document":"tm2317752-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465923068337/tm2317752-4_4seq1.xml","form_type":"4"}},{"id":2197558,"issuer":{"id":68888,"kind":"organization","name":"Astria Therapeutics, Inc.","symbol":"ATXS"},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-08-02T08:51:17.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on August 1, 2022, pursuant to the Astria Therapeutics, Inc. 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the option grant. This option is subject to vesting over a four year period, with 25% of shares vesting on the first anniversary of July 14, 2022, the reporting person's employment start date, and the remainder vesting over the ensuing three years at a rate of 2.0833% per month."}],"balance_after":100000,"derivative":{"exercise_price":3.87,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001104659-22-084988","document":"tm2222284-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1454789/000110465922084988/tm2222284-1_4seq1.xml","form_type":"4"}},{"id":2428502,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-21T21:15:17.000Z","date":"2022-01-19","kind":"grant","acquired":true,"shares":59744,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service."}],"balance_after":59744,"derivative":{"exercise_price":12.69,"expiration_date":"2032-01-18","underlying":"Common Stock","underlying_shares":59744},"source":{"system":"sec-edgar","filing":"0000899243-22-002878","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924322002878/doc4.xml","form_type":"4"}},{"id":2651108,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-06-29T20:16:32.000Z","date":"2021-06-28","kind":"purchase","acquired":true,"shares":1100,"price":9.16,"value":10076.0,"ownership":{"direct":true},"balance_after":1100,"source":{"system":"sec-edgar","filing":"0000899243-21-026557","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321026557/doc4.xml","form_type":"4"}},{"id":2715798,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":68897,"kind":"person","name":"Morabito Christopher","position":1,"cik":"0001859284","reported_name":"Morabito Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-12T20:30:29.000Z","date":"2021-05-10","kind":"grant","acquired":true,"shares":163000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 10, 2021 and is scheduled to vest 25% on the first anniversary of the vesting commencement date of May 10, 2021. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service."}],"balance_after":163000,"derivative":{"exercise_price":10.01,"expiration_date":"2031-05-09","underlying":"Common Stock","underlying_shares":163000},"source":{"system":"sec-edgar","filing":"0000899243-21-019264","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321019264/doc4.xml","form_type":"4"}}]}